Fig. 3: Distribution of the risk score, T-DM1 response, overall survival (OS), and progression-free survival (PFS) based on the 4-lncRNA classifier in the training, internal, and independent validation cohorts. | Cell Death Discovery

Fig. 3: Distribution of the risk score, T-DM1 response, overall survival (OS), and progression-free survival (PFS) based on the 4-lncRNA classifier in the training, internal, and independent validation cohorts.

From: A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study

Fig. 3

A Waterfall plot for the distribution of the risk score and response status of individual patients in the training (top panel), internal (middle panel), and independent (bottom panel) cohorts. B Objective response rates of the high- and low-score groups in the training (top panel), internal (middle panel), and independent (bottom panel) cohorts. C Comparison of PFS between the high- and low-score groups in the training (top panel), internal (middle panel), and independent (bottom panel) cohorts. D Comparison of OS between the high- and low-score groups in the training (top panel), internal (middle panel), and independent (bottom panel) cohorts. E Hazard ratios and p values for PFS and OS in the training, internal, and independent cohorts. We calculated hazard ratios (HRs) and p values via univariate Cox regression analysis and the log-rank test. All the statistical analyses were two-sided.

Back to article page